Antiretroviral Pharmacokinetics in the Paediatric Population

[1]  Arnold G. Vulto,et al.  Pharmacokinetics of the Protease Inhibitor Indinavir in Human Immunodeficiency Virus Type 1-Infected Children , 2001, Antimicrobial Agents and Chemotherapy.

[2]  B. Sadler,et al.  Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing , 2001, Antimicrobial Agents and Chemotherapy.

[3]  R. de Groot,et al.  Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection. , 2000, AIDS.

[4]  S. Szefler.  Meeting the needs of the modernization act: Challenges in developing pediatric therapies , 2000 .

[5]  G. Kearns,et al.  Impact of developmental pharmacology on pediatric study design: overcoming the challenges. , 2000, The Journal of allergy and clinical immunology.

[6]  M. Kurowski,et al.  Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. , 2000, AIDS.

[7]  D. Richman,et al.  In vivo antagonism with zidovudine plus stavudine combination therapy. , 2000, The Journal of infectious diseases.

[8]  S. Spector,et al.  Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. , 2000, Pediatrics.

[9]  C. Fletcher,et al.  Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[10]  V. Carey,et al.  Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. , 2000, AIDS research and human retroviruses.

[11]  M. Bassetti,et al.  Indinavir Pharmacokinetics and Parmacodynamics in Children with Human Immunodeficiency Virus Infection , 2000, Antimicrobial Agents and Chemotherapy.

[12]  M. Gersten,et al.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. , 1999, The New England journal of medicine.

[13]  M. Gersten,et al.  Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  L. Mofenson,et al.  A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). , 1999, AIDS.

[15]  S. Hetherington,et al.  Safety and Pharmacokinetics of Abacavir (1592U89) following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults , 1999, Antimicrobial Agents and Chemotherapy.

[16]  R. Yogev,et al.  Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children , 1999, Antimicrobial Agents and Chemotherapy.

[17]  J. Church,et al.  Serum and Cerebrospinal Fluid Pharmacokinetics of Intravenous and Oral Lamivudine in Human Immunodeficiency Virus-Infected Children , 1998, Antimicrobial Agents and Chemotherapy.

[18]  P. Harrigan,et al.  Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. , 1998, The Journal of infectious diseases.

[19]  S. Spector,et al.  Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. , 1998, The Journal of infectious diseases.

[20]  S. Spector,et al.  Zidovudine Pharmacokinetics in Premature Infants Exposed to Human Immunodeficiency Virus , 1998, Antimicrobial Agents and Chemotherapy.

[21]  S. Steinberg,et al.  A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection , 1998, Pediatrics.

[22]  E. Garvey,et al.  Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 , 1997, Antimicrobial agents and chemotherapy.

[23]  C. Taketomo,et al.  Pediatric Dosage Handbook , 1997 .

[24]  G. Forbes,et al.  BACK TO BASICS: Fluids and Electrolytes—Clinical Aspects , 1996 .

[25]  J. Sullivan,et al.  Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. , 1996, The Journal of infectious diseases.

[26]  J. Church,et al.  Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. , 1996, The Journal of infectious diseases.

[27]  J. Church,et al.  A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. , 1995, Pediatrics.

[28]  D. Back,et al.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. , 1995, British journal of clinical pharmacology.

[29]  D. Venzon,et al.  Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. , 1994, Pediatrics.

[30]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[31]  S. Pelton,et al.  Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. , 1993, The Journal of pediatrics.

[32]  C. Debouck,et al.  The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.

[33]  F. Balis,et al.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. , 1992, The Journal of infectious diseases.

[34]  J. Falloon,et al.  Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. , 1989, The Journal of pediatrics.

[35]  J. Falloon,et al.  The pharmacokinetics of zidovudine administered by continuous infusion in children. , 1989, Annals of internal medicine.

[36]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Broder,et al.  Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases , 1987, Clinical pharmacology and therapeutics.

[38]  William J. Jusko,et al.  Berichten , 2005, Pharmaceutisch weekblad.

[39]  S. Yaffe.  Pediatric pharmacology: Therapeutic principles in practice , 1980 .